Literature DB >> 934962

Neonatal hypoglycemia and hyperglycemia: two unique perinatal metabolic problems.

H S Dweck.   

Abstract

Hypoglycemia is a frequent, potentially morbid disease in the newborn. Most infants who are at risk can be identified either prior to or immediately after birth. A knowledge of those factors that cause or potentiate the development of hypoglycemia can alert the physician as to which infants require close observation and frequent monitoring of blood glucose. Care in interpretation of laboratory data is important in establishing the diagnosis. Prompt treatment can prevent permanent damage and promote intact survival in these infants. Hyperglycemia has been reported with the use of parenteral glucose in infants of very low birth weight. Rate of glucose infusion appears to be a critical factor in the development of hyperglycemia in these infants. The hazards of allowing fasting hypoglycemia to develop by inappropriate withholding of early calories and of causing hyperglycemia by injudicious use of parenteral glucose infusions in the tiny neonate show the critical need for constant monitoring of blood glucose both by screening techniques and by laboratory determinations.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 934962     DOI: 10.1080/00325481.1976.11714420

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  2 in total

1.  Comparative effects of glucose- and mannitol-induced osmolar stress on blood-brain barrier function in ovine fetuses and lambs.

Authors:  Barbara S Stonestreet; Grazyna B Sadowska; R Choudary Hanumara; Mihaela Petrache; Katherine H Petersson; Clifford S Patlak
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

2.  Analysis of the characteristics and management of critical values in a newborn tertiary center in China.

Authors:  Zheng-Li Wang; Li-Zhong Du; Yi-Yu Chen; Lu-Quan Li; Qi Lu; Ying Liu; Lu-Ying Cao; Yu He; Jia-Lin Yu
Journal:  World J Pediatr       Date:  2016-09-15       Impact factor: 2.764

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.